



## Thyrolar® (liotrix) – Product discontinuation

- On December 6, 2018, the [FDA announced](#) the discontinuation of Allergan's [Thyrolar \(liotrix\)](#) tablets.
  - The discontinuation was based on a business decision and is not due to product quality, safety, or efficacy concerns.
- Thyrolar is indicated as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis; and as a pituitary thyroid stimulating hormone suppressant, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, sub-acute or chronic lymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.